These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23735235)

  • 41. Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
    Rascol O
    Expert Opin Pharmacother; 2005 Oct; 6(12):2061-75. PubMed ID: 16197359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
    Silver DE; Buck PO
    Int J Neurosci; 2011 Sep; 121(9):485-9. PubMed ID: 21671840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
    Hauser RA; Abler V; Eyal E; Eliaz RE
    Int J Neurosci; 2016 Oct; 126(10):942-6. PubMed ID: 26988747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
    Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
    Cai JP; Chen WJ; Lin Y; Cai B; Wang N
    Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of minimal clinically important change in early and advanced Parkinson's disease.
    Hauser RA; Auinger P;
    Mov Disord; 2011 Apr; 26(5):813-8. PubMed ID: 21437987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of rasagiline in the treatment of Parkinson's disease.
    Leegwater-Kim J; Bortan E
    Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
    Nagai M; Hattori N
    Nihon Yakurigaku Zasshi; 2020; 155(3):187-194. PubMed ID: 32378642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rasagiline improves quality of life in patients with early Parkinson's disease.
    Biglan KM; Schwid S; Eberly S; Blindauer K; Fahn S; Goren T; Kieburtz K; Oakes D; Plumb S; Siderowf A; Stern M; Shoulson I;
    Mov Disord; 2006 May; 21(5):616-23. PubMed ID: 16450340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ; Jeong H; Chung YA; Park JS; Heo Y; Oh JK; Song IU
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
    Jankovic J; Berkovich E; Eyal E; Tolosa E
    Parkinsonism Relat Disord; 2014 Jun; 20(6):640-3. PubMed ID: 24637126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Stocchi F; Rascol O; Hauser RA; Huyck S; Tzontcheva A; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt DJ;
    Neurology; 2017 Jun; 88(23):2198-2206. PubMed ID: 28490648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rasagiline in Parkinson's disease.
    Chahine LM; Stern MB
    Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid onset of efficacy of rasagiline in early Parkinson's disease.
    Zambito Marsala S; Vitaliani R; Volpe D; Capozzoli F; Baroni L; Belgrado E; Borsato C; Gioulis M; Marchini C; Antonini A
    Neurol Sci; 2013 Nov; 34(11):2007-13. PubMed ID: 23636872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.